SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From BiohavenNews DeskAugust 30, 20260 SK Biopharmaceuticals, a South Korea-based drugmaker that already sells an FDA-approved epilepsy medicine, is expanding its U.S. strategy with a…